Geneva, June 20 -- International Clinical Trials Registry received information related to the study (NCT07020884) titled 'A Phase II Study of ZT002 Injection With Subjects With Overweight or Obesity' on June 6.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Beijing QL Biopharmaceutical Co.,Ltd
Condition:
Overweight or Obesity
Intervention:
Drug: ZT002 Injection
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 14, 2024
Target Sample Size: 300
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07020884
...